Home
About
Overview
Management
Board of Directors
Careers
Pipeline
Overview
Metabolic Disease Programs
VK2735 (Obesity, Metabolic Disorders)
VK2809 (NASH/MASH)
Rare Disease Program
VK0214 (X-ALD)
Other Pipeline Programs
VK5211 (Hip Fracture, Muscle Wasting)
VK0612 (Type 2 Diabetes)
VK1430 (Hypertriglyceridemia, NASH)
EPOR Agonist Program (Anemia)
Investors & Media
Overview
Stock Information
News & Events
SEC Filings
Analyst Coverage
Corporate Governance
Shareholder Services
Corporate Presentation
Contact
Developing novel therapeutics
for metabolic and endocrine disorders
0
Tweets
0
Likes
Home
About
Overview
Management
Board of Directors
Careers
Pipeline
Overview
Metabolic Disease Programs
VK2735 (Obesity, Metabolic Disorders)
VK2809 (NASH/MASH)
Rare Disease Program
VK0214 (X-ALD)
Other Pipeline Programs
VK5211 (Hip Fracture, Muscle Wasting)
VK0612 (Type 2 Diabetes)
VK1430 (Hypertriglyceridemia, NASH)
EPOR Agonist Program (Anemia)
Investors & Media
Overview
Stock Information
News & Events
SEC Filings
Analyst Coverage
Corporate Governance
Shareholder Services
Corporate Presentation
Contact